We are live on ! Find out more
CRL icon

Charles River Laboratories

407 hedge funds and large institutions have $5.16B invested in Charles River Laboratories in 2018 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 117 increasing their positions, 155 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $5.82M

141% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 32

11% more funds holding

Funds holding: 366407 (+41)

2.02% less ownership

Funds ownership: 97.11%95.09% (-2%)

18% less capital invested

Capital invested by funds: $6.27B → $5.16B (-$1.11B)

25% less repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 155

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
407
Holders Change
+41
Holders Change %
+11.2%
% of All Funds
9.07%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
77
Increased
117
Reduced
155
Closed
32
Calls
$18.3M
Puts
$5.82M
Net Calls
+$12.5M
Net Calls Change
+$931K
Name Holding Trade Value Shares
Change
Change in
Stake
Creative Planning
301
Creative Planning
Kansas
$265K +$62.7K +501 +27%
SAM
302
Symphony Asset Management
California
$256K -$8.76K -70 -3%
SAMH
303
Shanda Asset Management Holdings
British Virgin Islands
$250K +$276K +2,207 New
Connor, Clark & Lunn Investment Management (CC&L)
304
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$249K +$275K +2,200 New
AP
305
Advisor Partners
California
$240K +$9.02K +72 +4%
SL
306
Signition LP
New York
$227K +$251K +2,008 New
CA
307
Cambridge Advisors
Nebraska
$226K
SWP
308
Stratos Wealth Partners
Ohio
$225K
Jane Street
309
Jane Street
New York
$224K -$1.42M -11,332 -85%
WAM
310
World Asset Management
Michigan
$217K -$17.3K -138 -7%
II
311
Ibex Investors
Colorado
$217K +$240K +1,916 New
CIBC Private Wealth Group
312
CIBC Private Wealth Group
Georgia
$213K
VAM
313
Visionary Asset Management
Texas
$207K -$8.89K -71 -4%
CG
314
Caprock Group
Idaho
$206K
BMCM
315
Bryn Mawr Capital Management
Pennsylvania
$205K
Bessemer Group
316
Bessemer Group
New Jersey
$190K -$10.1K -81 -5%
ARMT
317
Amica Retiree Medical Trust
Rhode Island
$185K
QI
318
QS Investors
New York
$183K -$5.63M -44,959 -97%
Mitsubishi UFJ Asset Management
319
Mitsubishi UFJ Asset Management
Japan
$179K -$24.4K -195 -10%
MWNA
320
Marshall Wace North America
New York
$173K +$192K +1,530 New
BBHC
321
Brown Brothers Harriman & Co
New York
$172K +$2.88K +23 +2%
AWM
322
Avior Wealth Management
Nebraska
$168K +$187K +1,490 New
MAM
323
Meeder Asset Management
Ohio
$157K +$65.6K +524 +61%
APA
324
American Portfolios Advisors
New York
$153K -$9.64K -77 -5%
PI
325
PEAK6 Investments
Illinois
$148K +$163K +1,305 New

CRL Hedge Fund Activity: Q4 2018 in Review

407 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2018, worth a combined $5.16B — down 18% from $6.27B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new CRL positions and 32 closed out — a net gain of 45 holders — while 117 added to existing stakes and 155 trimmed.

The largest buyer was Epoch Investment Partners, opening a new position worth an estimated $43.1M. The largest seller was Fidelity International, cutting an estimated $96.6M.

  • 407 institutional investors held Charles River Laboratories (CRL) as of Q4 2018, up from 366 in Q3 2018.
  • Funds reported $5.16B of Charles River Laboratories stock for Q4 2018, down 18% quarter-over-quarter.
  • 77 funds opened new Charles River Laboratories positions in Q4 2018 and 32 closed out, a net change of +45 holders.
  • The largest Charles River Laboratories buyer in Q4 2018 was Epoch Investment Partners, an estimated $43.1M added.
  • The largest Charles River Laboratories seller in Q4 2018 was Fidelity International, an estimated $96.6M sold.

Based on aggregated 13F filings for Q4 2018.